The Fund supports networks of state health policy decision makers to help identify, inspire, and inform policy leaders.
The Milbank Memorial Fund supports two state leadership programs for legislative and executive branch state government officials committed to improving population health.
The Fund identifies and shares policy ideas and analysis to advance state health leadership, strong primary care, and sustainable health care costs.
Keep up with news and updates from the Milbank Memorial Fund. And read the latest blogs from our thought leaders, including Fund President Christopher F. Koller.
The Fund publishes The Milbank Quarterly, as well as reports, issues briefs, and case studies on topics important to health policy leaders.
The Milbank Memorial Fund is is a foundation that works to improve population health and health equity.
August 4, 2025
Quarterly Article
Rick Mayes
Micah Johnson
Jul 2, 2025
June 2025
Back to The Milbank Quarterly – Old
Policy Points:
From 2004 to 2024, Medicare Advantage (MA) went from being a “policy disappointment,” covering 12% of all Medicare beneficiaries, to predominance, covering more than one-half (52%), with more growth predicted in the future. Drawing on an extensive review and synthesis of the literature, Medicare Payment Advisory Commission (MedPAC) reports, congressional committee hearings, and Centers for Medicare and Medicaid Services (CMS) data, this paper analyzes the evolution of Medicare and managed care in three parts. First, it briefly traces the early efforts to build an integrated managed care option to the traditional, fragmented fee-for-service Medicare program and highlights four key changes in federal policy that set the stage for the significant expansion of MA after the passage of the Affordable Care Act (ACA) in 2010. Second, it outlines the current structure of MA and contrasts it with traditional Medicare (TM). Third, it reviews a few major changes that could reform and improve MA, including the standardization of MA plan types for which private health plans would competitively bid. It concludes with the observation that the growth of MA, which integrates and expands TM benefits, has resulted in a program that now annually costs an estimated $84 billion more than what Medicare would spend if its enrollees were in TM. This differential in payments has significantly advantaged MA relative to TM and transformed the Medicare program by corporatizing it for tens of millions of beneficiaries. Additionally, it has raised the specter of interest group capture of MA by the largest health plan providers that can outmaneuver government regulators on behalf of senior beneficiaries to whom policymakers are beholden.